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Abstract17
The present work aimed at designing a lipid-based nanocarrier for siRNA delivery18
towards two cell sub-populations within breast tumors, the cancer and the endothelial 19
cells from angiogenic tumor blood vessels. To achieve such goal, the F3 peptide, which 20
is specifically internalized by nucleolin overexpressed on both those sub-populations, 21
was used as a targeting moiety. 22
The developed F3-targeted stable nucleic acid lipid particles presented adequate features 23
for systemic administration. In addition, the attachment of the F3 peptide onto the 24
liposomal surface enabled an internalization by both cancer and endothelial cells from 25
angiogenic blood vessels that was significantly higher than the one observed with non-26
cancer cells. Sequence-specific downregulation of enhanced green fluorescent protein 27
(eGFP) in eGFP-overexpressing human cancer cell lines, both at the protein and mRNA 28
levels, was further observed upon delivery of anti-eGFP siRNA by F3-targeted 29
liposomes, in contrast with the non-targeted counterpart. This effect was highly 30
dependent on the content of poly(ethylene glycol) (PEG), as evidenced by the co-31
localization studies between the siRNA and lysosomes.   32
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Overall, the present work represents an important contribution towards a nanoparticle 33
with multi-targeting capabilities in breast cancer, both at the cellular and molecular 34
level.35
36
Keywords: dual-targeted delivery, ligand-mediated targeting, Stable Nucleic Acid 37
Lipid Particles (SNALP), siRNA, breast cancer.38
39
1. Introduction40
Cancer is still a severe public health problem being one of the most deadly diseases in 41
the western world (Jemal et al., 2011). The limited effectiveness of conventional 42
treatment strategies has generated considerable interest on the development of novel43
anticancer agents, with improved molecular target specificity. In this context, small-44
interfering RNA (siRNA), 21-23 nucleotides long double-stranded RNA that inhibit the 45
expression of a target gene through specific cleavage of perfectly complementary 46
mRNA (Elbashir et al., 2001a; Elbashir et al., 2001b; Fire et al., 1998), may constitute a 47
novel class of pharmaceutical drugs, as they can potently and specifically  inhibit the 48
expression of any intracellular protein involved in tumor initiation and/or progression. 49
However, the translation of these molecules from the bench to the clinic has been 50
hindered by their limited cellular uptake, low biological stability and unfavorable 51
pharmacokinetics (Castanotto and Rossi, 2009; Moreira et al., 2008). 52
In order to overcome the mentioned limitations, different types of poly(ethylene glycol) 53
(PEG)-grafted liposomes have been developed such as, stabilized antisense lipid 54
particles (SALP) (Maurer et al., 2001; Semple et al., 2001), or the related stabilized 55
nucleic acid lipid particles (SNALP) encapsulating siRNA (Akinc et al., 2010; Geisbert 56
et al., 2006; Judge et al., 2009; Morrissey et al., 2005; Zimmermann et al., 2006). The 57
PEG-derivatized lipid in the liposomal formulation forms a hydrophilic shell around the 58
liposomes that, upon intravenous administration, decreases the rate and the extent of 59
electrostatic and hydrophobic interactions between the surface of liposomes and blood 60
components that mediate liposomal blood clearance (Allen and Hansen, 1991; Allen et 61
al., 1991; Papahadjopoulos et al., 1991). In addition, those systems are also 62
characterized by high nucleic acid encapsulation, nucleic acid protection from serum 63
nucleases, a small average size, and a net charge close to neutrality, thus making them 64
adequate for intravenous administration. Although pegylated systems can exhibit 65
passive accumulation into a tumor due to their large fenestrated endothelium (enhanced 66
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permeability and retention, EPR, effect (Fang et al., 2011; Iyer et al., 2006)), large 67
improvements can be achieved through the covalent attachment of internalizing68
targeting ligands, which will interact specifically with receptors overexpressed on the 69
surface of target cells (Moreira et al., 2008; Torchilin, 2010). 70
However, the design of novel targeted anticancer strategies must take into account that 71
the aggressiveness of a tumor does not rely only on the cancer cell, but rather on the 72
cross-talk between cancer cells and other cells from the tumor microenvironment such 73
as, the endothelial cells (Hanahan and Weinberg, 2011). Thus, targeting angiogenesis, 74
in addition to cancer cells, can significantly improve clinical efficacy, as tumor growth 75
and metastases formation are angiogenesis-dependent (Abdollahi and Folkman, 2010). 76
Furthermore, vascular targeting carries some additional advantages since endothelial 77
cells are more accessible (than cancer cells) to the therapeutic agent injected in the 78
vascular compartment, and are less prone to acquire drug resistance. In addition, 79
treatment selectivity can be achieved, as, besides tumors, the formation of new blood 80
vessels is restricted to a few physiological processes such as wound healing, ovulation 81
and pregnancy (Abdollahi and Folkman, 2010). 82
The F3 peptide, which is specifically internalized by nucleolin, a receptor overexpressed 83
on the surface of cancer and endothelial cells of tumor blood vessels, offers the 84
possibility to develop dual-targeting strategies for nucleic acid delivery (Christian et al., 85
2003; Porkka et al., 2002). 86
Therefore, the main aim of this work was to design F3-targeted SNALP for the 87
encapsulation, protection and effective intracellular delivery of siRNA to two cell 88
populations within a tumor: the cancer cells and the endothelial cells from angiogenic 89
blood vessels. 90
91
2. Materials and methods92
2.1 Materials93
Lipids, 1,2-dioleoyl-3-dimethylammonium-propane (DODAP), 1,2-distearoyl-sn-94
glycero-3-phosphocholine (DSPC), N-Palmitoyl-Sphingosine-1-95
[Succinyl(MethoxyPolyethylene Glycol)2000] (CerC16-PEG2000),  1,2-Distearoyl-sn-96
Glycero-3-Phospatidylethanolamine-N-[Maleimide (Polyethylene Glycol)2000] 97
ammonium salt (DSPE-PEG-MAL) and L-α-Phosphoethanolamine-N-(lissamine 98
rhodamine B sulfonyl) (Rho-PE) were purchased from Avanti Polar Lipids (USA). The 99
lipid, cholesterol (CHOL), was obtained from Sigma (Germany).  100
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The anti-eGFP siRNA (5´GAA CUU CAG GGU CAG CUU GCdTdT -3´), the control 101
siRNA (5´- GUC UCA AGU UUU CGG GAA GdTdT -3´) and the FITC-labelled anti-102
eGFP siRNA were purchased from Dharmacon (USA). 103
The 31 aminoacid F3 peptide (KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK) and 104
the non-specific (NS) peptide were purchased from Genecust (Luxembourg) (Porkka et 105
al., 2002).106
107
2.2 Cell lines108
The human breast cancer cell lines, MDA-MB-435S and MDA-MB-231, and the human 109
fibroblasts, BJ, were from American Type Culture Collection (ATCC). The human 110
microvascular endothelial cell line, HMEC-1, was a generous gift from the Center for 111
Disease Control and Prevention (USA). 112
MDA-MB-435S and MDA-MB-231 were cultured in RPMI 1640 medium (Sigma, 113
Germany) and human fibroblasts cells, BJ, were cultured in DMEM medium (Sigma, 114
Germany). Both media were supplemented with 10% (v/v) heat-inactivated foetal 115
bovine serum (Invitrogen, USA), and 100 U/ml penicillin, 100 µg/ml streptomycin 116
(Invitrogen, USA). HMEC-1 cells were cultured in RPMI 1640 supplemented with 10 117
ng/ml of mouse epidermal growth factor (mEGF) (Sigma, Germany) and 1 µg/ml 118
hydrocortisone (Sigma, Germany). Cells were maintained in exponential growth phase, 119
at 37ºC, in a 90% humidified atmosphere containing 5% CO2.120
121
2.3 Preparation of sterically stabilized liposomes 122
Preparation of stabilized nucleic acid lipid particles (SNALP) was adapted from Semple 123
et al. (Maurer et al., 2001; Semple et al., 2001). A lipid mixture of 124
DODAP:DSPC:CHOL:CerC16-PEG2000 (30:23:45:2, 30:21:45:4 or 30:15:45:8, % molar 125
ratio relative to total lipid, 13 µmol) in absolute ethanol and 0.046 µmol of anti-eGFP 126
siRNA or of a non-specific siRNA in 20 mM citrate buffer, pH 4, were heated at 65ºC. 127
For cellular association and internalization studies, nanoparticles were double-labelled 128
with anti-eGFP FITC-labelled siRNA and 1 mol % of Rho-PE. 129
The lipid mixture was added, slowly and under strong agitation, to the siRNA solution. 130
The resulting particles were then extruded 21 times through polycarbonate membranes 131
of 100 nm pore diameter, using a LiposoFast basic extruder (Avestin, Canada). 132
Removal of ethanol and non-encapsulated siRNA was carried out upon running 133
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extruded nanoparticles through a Sepharose CL-4B column equilibrated with HEPES 134
buffered saline (HBS) (20 mM HEPES, 145 mM NaCl), pH 7.4. 135
136
2.4 Preparation of targeted liposomes137
Targeted liposomes were prepared by the post-insertion method (Moreira et al., 2002; 138
Santos et al., 2010). Briefly, F3 and NS peptides were first thiolated upon reaction with 139
2-iminothiolane in HBS, pH 8, during 1 h at room temperature, in an inert N2 140
atmosphere. They were then coupled to DSPE-PEG-MAL micelles, prepared in MES 141
buffered saline (MBS) (20 mM MES, 20 mM HEPES), pH 6.5. Insertion of DSPE-142
PEG-MAL-F3 or DSPE-PEG-MAL-NS conjugates onto the preformed sterically 143
stabilized liposomes previously prepared, took place upon incubation of the 144
corresponding micelles with the latter at 50ºC for 1 h. For the non-targeted lipid 145
particles, post-insertion was performed only with plain DSPE-PEG-MAL micelles. 146
Neutralization of non-reacted maleimide groups was performed upon incubation with 2-147
mercaptoethanol at a maleimide/2-mercaptoethanol molar ratio of 1:5. Finally, 148
liposomes were run through a Sepharose CL-4B column equilibrated with HBS, pH 7.4.149
150
2.5 Characterization of the liposomes151
The final total lipid concentration was inferred from the cholesterol concentration,152
determined with the Infinity® liquid stable reagent (Thermo Scientific, USA). The 153
quantification of the siRNA that was encapsulated into the liposomes was determined 154
with the Quanti-iTTM Ribogreen reagent (Invitrogen, USA), in the presence of 155
octaethylene glycol monododecyl ether (C12E8) detergent (Sigma, Germany). The 156
encapsulation efficiency was calculated from the formula [(siRNA/total lipid)final molar 157
ratio/(siRNA/total lipid)initial molar ratio]x100. In order to assess if the siRNA was fully 158
encapsulated and protected by the lipid nanoparticle, the ability of the probe Quant-iTTM159
Ribogreen to intercalate with siRNA, in the absence of the detergent C12E8, was 160
evaluated.161
The mean diameter of the resulting liposomes was determined by Photon Correlation 162
Spectroscopy, using a N5 submicron particle size analyser (Beckman Coulter). The zeta 163
potential was assessed using a Particle Size Analyzer 90 Plus (Brookhaven).164
To determine the amount of DSPE-PEG-MAL-F3 conjugate that was transferred onto 165
the preformed liposomes, the F3 peptide was quantified using the CBQCA protein 166
quantification Kit (Invitrogen, USA).167
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2.6 Assessment of cellular association by flow cytometry 169
Half million of cancer, fibroblast or endothelial cells were seeded in 48-well plate. 170
Twenty four hours later, cells were incubated at 37 or 4ºC, during 1 h, with rhodamine-171
labelled F3-targeted, NS-targeted or non-targeted liposomes, at 0.2, 0.4 or 0.6 mM of 172
total lipid. Afterwards, cells were washed three times with phosphate buffer saline 173
(PBS), pH 7.4, detached with dissociation buffer and immediately analyzed by flow 174
cytometry using a FACS Calibur flow cytometer (BD, Biosciences). Rhodamine 175
fluorescence was evaluated in the FL2 channel and a total of 20.000 events were 176
collected. Data were analyzed with the Cell Quest Pro software.177
178
2.7 Assessment of cellular internalization by confocal fluorescence microscopy179
For the confocal studies, 2.5x105 of cancer, fibroblast or endothelial cells were seeded 180
on glass cover slips in 12-well plate and further incubated, at 37 or 4ºC, during 1 h, with 181
1 μM of FITC-labelled siRNA encapsulated in rhodamine-labelled liposomes (F3-182
targeted or non-targeted). After washing three times with PBS, cells were fixed with 4% 183
paraformaldeyde, and the nucleus stained with DAPI, washed with PBS, and finally, 184
mounted in mowiol mounting medium. Confocal images were acquired in a Zeiss LSM-185
510 point scanning confocal microscope (Zeiss, Germany), using a diode (405 nm), an186
argon (488 nm) and a DPSS excitations lasers for DAPI, FITC and Rhodamine, 187
respectively, and a 63x oil immersion objective. Images were acquired and analyzed 188
using the LSM 510 Meta software. All instrumental parameters pertaining to 189
fluorescence detection and images analyses were held constant to allow sample 190
comparison. 191
192
2.8 Evaluation of eGFP levels by flow cytometry193
Human cancer cell lines overexpressing eGFP, MDA-MB-435S-eGFP and MDA-MB-194
231-eGFP, were used to evaluate the potential of the F3-targeted liposomes to 195
downregulate a target protein. EGFP was used as a model target as its downregulation 196
could be easily assessed upon measuring fluorescence by flow cytometry, thus 197
facilitating the assessment of the delivery properties of each one of the formulations to 198
be tested.199
In order to evaluate the downregulation of eGFP, 30.000 cells were seeded in 48-well200
plates. Twenty-four hours later, cells were transfected, at 37ºC during 4 h, with different 201
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concentrations of anti-eGFP siRNA encapsulated in F3-targeted or non-targeted202
liposomes, or a non-specific siRNA encapsulated in the former. Afterwards, cell culture 203
medium was replaced with fresh medium and a second transfection was performed 44 h 204
after the beginning of the experiment, with the same formulations and concentrations 205
used in the first transfection. In another set of experiments, single transfections were 206
performed right at the beginning of the experiment, at 37ºC during 4 h.  In these 207
experiments, 48 or 96 h after the beginning of the experiment, cells were detached and 208
eGFP levels were evaluated by flow cytometry using a FACS Calibur flow cytometer 209
(BD, Biosciences).210
EGFP fluorescence was evaluated in the FL1 channel and a total of 20,000 events were 211
collected. Data were then analyzed with the Cell Quest Pro software. The eGFP212
fluorescence reduction was expressed in percentage of the ratio: 100 - [(eGFP signal of 213
treated cells/eGFP signal of untreated cells) x 100]. 214
215
2.9 Intracellular trafficking of siRNA encapsulated in F3-targeted liposomes216
In order to investigate whether siRNA encapsulated in the developed F3-targeted 217
liposomes could efficiently escape from endosomes, co-localization studies between the 218
siRNA and lysosomes were performed in MDA-MB-435S cells.219
Cancer cells were seeded on µ-slide 8-well ibitreat plates (Ibidi, Germany).  After 24 h, 220
cells were incubated with F3-targeted liposomes encapsulating a FITC-labelled siRNA, 221
during 4 h at 37ºC. Afterwards, lysosomes were stained upon cell incubation with 100 222
nM LysoTracker Red (Invitrogen, USA) for 2 h, followed by washing three times with 223
PBS. Live cells were then immediately visualized using an argon (488 nm), a DPSS224
(561 nm) and a helium-neon (633 nm) excitations lasers for FITC, Lysotracker Red and 225
differential interference contrast (DIC), respectively, and a 63x oil immersion objective. 226
Images were acquired and analyzed as previously described. 227
228
2.10 Evaluation of eGFP mRNA by quantitative real-time reverse-transcription 229
PCR (qRT-PCR)230
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In order to confirm that the eGFP reduction observed by flow cytometry was due to an 231
RNA interference mechanism, the levels of eGFP mRNA were determined by qRT-232
PCR, 24 h after the second transfection (72 h after the beginning of the experiment).233
Cells were harvested and RNA extracted with RNeasy Mini Kit (Qiagen, Germany) 234
according to the manufacturer´s instructions. The Quanti-iTTM Ribogreen reagent was 235
used to quantify the extracted RNA, where 0.5 µg of RNA was reversed transcribed into 236
cDNA in a 20 µl reaction mixture using the SuperSriptTM III First Strand Synthesis 237
Supermix (Invitrogen, USA) following the manufacturer´s instructions. 238
Quantitative real-time PCR (q-PCR) was performed using the IqTMSYBR Green 239
Supermix (Bio-Rad, USA). Beta-2-microglobulin (β2M) was used as the endogenous 240
control (housekeeping gene). The forward primer for β2M was 5´-241
GAGTATGCCTGCCGTGTG-3´ and the reverse primer was 5´-242
AATCCAAATGCGGCATCT-3´ (Microsynth, Switzerland). For eGFP, the 243
QuantiTectTM Primer Assay (Qiagen, Germany) was used.244
The optimized qPCR conditions included the activation of HotStartTaq Plus DNA 245
polymerase followed by 40 cycles of two steps: a first step of denaturation (10 s at 95ºC) 246
and a second step of combined annealing/extension (30 s at 60ºC). After the qPCR, a 247
melting curve analysis of the PCR products was performed to confirm their specificity. 248
The threshold cycle (Ct) values were generated by the iQ5 Optical System Software. 249
The level of eGFP mRNA was calculated by the Livak method, 2-ΔΔCt x 100, where 250
ΔΔCt = (Ct eGFP – Ct β2M) treated - (Ct eGFP – Ct β2M) untreated. The application 251
of this method relied on the similar PCR efficiencies between the target gene and the 252
housekeeping gene.253
254
2.11 Statistical analysis 255
The results are presented as the mean ± standard deviation (SD) of at least three 256
independent experiments. One- or two-way ANOVA with Bonferroni´s post-test was 257
used to determine statistically significant differences of the means. Statistical 258
differences are presented at probability levels of p>0.05, p< 0.05, p <0.01, and p<0.001.259
260
3. Results261
3.1 Preparation and physico-chemical characterization of F3-targeted and non-262
targeted liposomes 263
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The pharmacokinetics and biodistribution of any encapsulated drug, regardless its 264
nature, are highly dependent on the physico-chemical properties of the liposomes, 265
including size, surface charge, level of protection against nucleases and the presence of 266
targeting moieties at the surface that are specifically recognized by internalizing 267
receptors overexpressed on the target cells (Li and Huang, 2008). 268
It is well recognized that PEG plays an important role preventing particle aggregation 269
during the preparation process (Maurer et al., 2001). Therefore the impact of the 270
incorporation of different amounts of CerC16-PEG2000 (2, 4, and 8 mol% relative to total 271
lipid) on the final size of the liposomes was evaluated. For F3-targeted liposomes, an 272
increase in the amount of the PEG-derivatized lipid, from 2 to 4%, led to a decrease on 273
the mean size of the particles reaching values around 200 nm, while exhibiting a narrow 274
particle distribution as the polydispersity index was in the range of 0.14 - 0.15 (Table 275
1). We have also verified that the length of the encapsulated siRNA influenced the 276
liposomal mean size. A difference as small as 1 nt on the siRNA length, has resulted in 277
a reduction of around 50 nm in the mean size of targeted liposomes with 2 mol% of 278
CerC16-PEG2000 (205.70 ± 18.55 nm).279
The attachment of the F3 peptide to the surface of liposomes was performed by the 280
insertion (Ishida et al., 1999; Moreira et al., 2002) of DSPE-PEG-MAL-F3 conjugates281
onto preformed liposomes, leading to an average amount of 4 nmol of F3 peptide per 282
µmol of total lipid. Importantly, this procedure has not interfered with the loading of the 283
encapsulated nucleic acids since encapsulation efficiencies close to 100% have been284
observed for both non-targeted and F3-targeted liposomes (Table 1). This high siRNA 285
encapsulation efficiency was certain due to the inclusion in the lipid bilayer of the 286
ionizable lipid DODAP, which is positively charged at low pH. However, after siRNA 287
encapsulation, adjustment of the external pH to neutral pH resulted in nanoparticles 288
close to neutrality, which reduces their ability to interact with serum proteins that 289
mediate an early clearance from the blood stream (Li and Huang, 2008). Non-targeted 290
liposomes were slightly negative (-4.83 ± 1.23 mV) while F3-targeted liposomes (0.37 ± 291
3.48 mV) exhibit a net surface charge close to neutrality likely due to the presence of 292
the F3 peptide on the surface of the particle, which is rich in lysines and thus positively 293
charged.294
Regarding the level of nucleic acid protection in both formulations tested, it was 295
observed that in the absence of the membrane-disrupting detergent C12E8, the probe 296
Quant-iTTM Ribogreen was not able to intercalate with the encapsulated siRNA, 297
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translated in levels of protection close to 100%. These results indicated that the 298
nanoparticles were efficiently playing one of their primary roles, which consist in the 299
protection against nuclease-mediated degradation. 300
301
Insert Table 1302
303
3.2 Cellular association studies304
At 37ºC, the level of cellular association of F3-targeted liposomes was significantly 305
higher than the one observed for the non-targeted liposomes or liposomes coupled to a 306
non-specific peptide. These results indicated that the presence of the F3 peptide at the 307
liposomal surface brought an important gain, as it mediated an important improvement 308
on the extent of cellular association by breast cancer cells, including the triple negative 309
MDA-MB-231 cells, and the endothelial cells from angiogenic blood vessels, HMEC-1 310
as well (Marchio et al., 2004). 311
Upon incubation with 0.4 mM of total lipid, a 12-fold or a 14-fold increase in the 312
rhodamine signal for both MDA-MB-231 and HMEC-1 cells or MDA-MB-435S cell 313
lines, respectively, was observed. Regardless the histological origin of the cells, the 314
cellular uptake was dose-dependent (Figure 1 A).315
The interaction of the developed F3-targeted liposomes revealed to be peptide-specific 316
as it was pointed out by the low level of cellular association observed with the 317
liposomes coupled to a non-specific peptide. Moreover, in similar experiments 318
performed with a non-cancer (negative control) cell line, BJ fibroblasts, the previous 319
mentioned differences between F3-targeted and non-targeted liposomes were dissipated, 320
thus indicating that the interaction of the former with the target cells was also tumor 321
cell-specific. This observation is of high relevance as it strongly indicated that the 322
proposed strategy would avoid the internalization by normal tissues, thus reducing its 323
potential toxicity (Figure 1 A). 324
Incubation of F3-targeted liposomes at 4ºC, a temperature non-permissive for 325
endocytosis, strongly inhibited cellular association when compared to incubations at 37 326
ºC, a condition where both binding and endocytosis take place. These results suggested 327
that an energy-dependent process, most likely receptor-mediated endocytosis, was328
involved in the uptake of F3-targeted liposomes (Figure 1 B).329
330
Insert Fig. 1331
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332
In order to confirm the previous results, additional cellular association studies were 333
performed and cells analyzed by confocal microscopy. After 1 h of incubation, F3-334
targeted liposomes were localized in the cytoplasm of cancer (MDA-MB-435S and 335
MDA-MB-231) and endothelial cells (HMEC-1), as can be observed by the intense red 336
and green fluorescence, from rhodamine (marker of the liposomal membrane) and FITC 337
(labelling the encapsulated nucleic acid), respectively. This pattern was not visible 338
neither in the non-cancer BJ fibroblasts nor when any of the tested cells were incubated 339
with non-targeted liposomes.  In addition, when MDA-MB-435S cells were incubated 340
with F3-targeted liposomes, at 4ºC, no significant levels of internalization were 341
observed (Figure 2). Overall, these findings corroborate the previous results observed 342
by flow cytometry thus, also reinforcing the cell-specific interaction of the developed 343
targeted liposomes.344
345
Insert Fig. 2346
3.4 Evaluation of eGFP levels347
For proof-of-concept on the intracellular delivery capabilities of each one of the tested 348
formulations, MDA-MB-435 and MDA-MB-231 cells overexpressing the enhanced 349
green fluorescence protein (eGFP) were used, along with a siRNA against eGFP. 350
When cells were transfected twice with anti-eGFP siRNA delivered by F3-targeted 351
liposomes incorporating 2 mol% of CerC16-PEG2000 (Figure 3 A, B), a significant 352
concentration-dependent downregulation of the target protein was observed in both 353
MDA-MB-435S (from 19.9 to 42.7%) and MDA-MB-231 (from 17.9 to 29.9%), upon 354
assessment at 96 h after the beginning of the experiment.  These results emphasized the 355
importance of the intracellular delivery of the nucleic acid on its activity, as a total 356
absence of eGFP silencing was registered with the non-targeted counterpart. The 357
difference on the extent of eGPF silencing between these two cell lines, was likely 358
related with the higher extent of cellular association (and internalization) by the MDA-359
MB-435S cells (Figures 1 and 2).360
Interestingly, for the same 96 h duration of the experiment no significant differences in 361
the level of eGFP silencing were observed upon performing a single transfection 362
(Figure 3 A, B).  Moreover, eGFP signal reduction in MDA-MB-435S-eGFP, 48 h after 363
one single transfection, was lower than the one observed at 96 h (22.3 versus 36.1%, at364
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2 µM siRNA; p<0.001) (Figure 3 A, C). Taken together, these results reflect the ability 365
of the siRNA to be recycled intracellularly over time, thus propagating gene silencing 366
(Hutvagner and Zamore, 2002) and, the low turnover of the target protein as well (Li et 367
al., 1998). The siRNA concentrations required with the proposed F3-targeted strategy 368
were higher than the ones used with regular agents for in vitro transfection, like 369
lipofectamine (data not shown), however, they were in accordance with other reports on 370
ligand-mediated targeted (PEGylated) liposomes for the delivery of nucleic acids (Di 371
Paolo et al., 2011; Mendonca et al., 2010).372
In order to assess if liposomes with a higher PEG content and therefore more stable 373
from a physical point of view, still maintained the capacity to silence a target protein, 374
MDA-MB-435S-eGFP cells were transfected with anti-eGFP siRNA delivered by F3-375
targeted liposomes incorporating 4 or 8 mol% of CerC16-PEG2000.  Transfection with 4 376
mol% of PEG F3-targeted liposomes still enabled downregulation of the target protein 377
(Figure 3 D) but to a lesser extent than the counterpart incorporating 2 mol% PEG 378
(Figure 3 A), whereas the presence of 8 mol% PEG completely prevented gene 379
silencing (data not shown). In MDA-MB-231-eGFP cells a total absence of eGFP 380
silencing was observed even with targeted liposomes incorporating 4 mol% PEG (data 381
not shown). These results were likely related with the lower extent of liposomal uptake 382
by the MDA-MB-231, relative to the MDA-MB-435.383
In all the experiments performed, none of the tested formulations had a significant 384
impact on cell viability (data not shown).385
386
Insert Fig 3387
388
3.5 The inhibitory effect of PEG on the cellular association and intracellular 389
trafficking390
To better understand the effect of PEG on the transfection efficiency, we have first 391
evaluated the extent of cellular association of F3-targeted liposomes incorporating 2 or 392
8 mol% of PEG. In fact, a slight decrease on the level of cellular association was 393
observed for the formulation incorporating the highest amount of PEG (Figure 4).394
However, these results did not explain per se the absence of protein downregulation 395
associated with this formulation, as significant extent of association with the target cells 396
was still achieved. 397
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Being aware of how critical an efficient endosomal escape is for nucleic acids 398
bioavailability and pharmacodynamics, the co-localization between FITC-labelled 399
siRNA (green), delivered by each of those nanoparticles, with lysotracker red-labelled 400
lysosomes (red) was assessed following an incubation period of 4 h. The strong yellow 401
staining following incubation with targeted liposomes prepared with 8 mol% of PEG, 402
suggested a higher extent of co-localization between siRNA and lysosomes (Figure 5 403
A). In contrast, following delivery by liposomes with 2 mol% of PEG, a decrease on the 404
intensity of the yellow staining suggested a decrease on the extent of co-localization 405
(Figure 5 B). Overall, these results suggested that the high content of PEG strongly 406
impair the siRNA endosomal escape, thus justifying the lack of activity of anti-eGFP407
siRNA delivered by F3-targeted liposomes incorporating 8 mol% of PEG. 408
409
Insert Fig 4410
411
Insert Fig 5412
413
3.6 Evaluation of eGFP mRNA by qRT-PCR414
Incubation of MDA-MB-435S-eGFP cells with F3-targeted liposomes containing the 415
anti-eGFP siRNA led to an effective impact at the mRNA level, achieving a 416
downregulation of 50% at 2 µM siRNA. This effect was dependent on the siRNA 417
concentration (Figure 6), as was also observed at the protein level by flow cytometry 418
(Figure 3). With non-targeted liposomes containing the anti-eGFP siRNA or F3-419
targeted liposomes containing a control siRNA, no significant downregulation of eGFP420
mRNA was observed (Figure 6), evidencing both the molecular specificity of this421
approach and the importance of the intracellular delivery as well. Overall, these results 422
pointed out the strong benefit of F3-targeted liposomes as a platform for the delivery of 423
siRNA.424
425
Insert Fig 6426
427
4. Discussion428
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As a therapeutic approach, gene silencing molecules, and particularly siRNA, provide429
solutions to the major drawbacks of traditional pharmaceutical drugs. The principal430
advantage over small molecules and protein therapeutics are that all targets, including 431
‘non-druggable’ targets, can be inhibited by siRNA, which can be rapidly and rationally 432
screened, designed and synthesized (Bumcrot et al., 2006). 433
Although siRNAs are one of the most promising class of RNAi mediators for 434
therapeutic purposes, the clinical advancement of this strategy has been difficult to 435
reach.  This is particularly relevant when intravenous administration is envisaged as 436
naked siRNAs are easily degraded by blood nucleases, rapidly eliminated by the 437
kidneys and highly internalized by the reticuloendothelial system. Furthermore, even if 438
the target cells are reached, the negative charge and hydrophilic nature of siRNAs 439
strongly impair the cellular internalization (Castanotto and Rossi, 2009; Moreira et al., 440
2008). Such limitations emphasize the need for an efficient and safe system to modulate 441
the siRNA pharmacokinetics and biodistribution.442
In this respect, SALP (Maurer et al., 2001; Semple et al., 2001) and SNALP (Akinc et 443
al., 2010; Geisbert et al., 2006; Judge et al., 2009; Morrissey et al., 2005; Zimmermann 444
et al., 2006) fulfilled some of the requisites that should be present in a nanoparticle for 445
intravenous administration of siRNA such as, high encapsulation efficiency, protection 446
against nucleases, a small mean size, charge close to the neutrality and, prolonged blood 447
circulation times. Nevertheless, those features are not enough to dictate an effective 448
systemic siRNA delivery to distan  sites of disease, like solid tumors localized in organs 449
other than the liver. Actually, most of the studies involving sterically stabilized 450
liposomes containing nucleic acids demonstrated that these particles naturally 451
accumulate in the liver and spleen (Akinc et al., 2010; Geisbert et al., 2006; Judge et al., 452
2009; Kim et al., 2007; Morrissey et al., 2005; Zimmermann et al., 2006), being the 453
accumulation into solid tumors still an enormous challenge. Despite this constraint, the 454
aforementioned classes of liposomes represent an opportunity for further improvements 455
on the targeted delivery to solid tumors upon covalently coupling of ligands targeting 456
internalizing receptors.   Antagonist G (Santos et al., 2010), transferrin (Mendonca et 457
al., 2010) and folate (Yang et al., 2004) are examples of ligands which have been 458
explored as targeting devices of nanoparticles of different nature, including liposomes 459
similar to the ones herein described. However, these strategies aiming at targeting 460
cancer cells have not increased the level of tumor accumulation, in comparison to their 461
non-targeted counterpart, but rather the intracellular delivery of those liposomes that 462
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were able to cross the leaky tumor endothelium.  In the work of Moreira et al. (Moreira 463
et al., 2001a; Moreira et al., 2001b), tumor accumulation of antagonist G-targeted 464
liposomes and the non-targeted counterpart was similar, despite the enhanced cellular 465
internalization observed in vitro of the former. Moreover, Bartlett et al. (Bartlett et al., 466
2007) also demonstrated that both non-targeted and transferrin-targeted siRNA 467
polymer-based nanoparticles exhibited similar biodistribution and tumor accumulation. 468
These results demonstrated that tumor accumulation of both cancer cell-targeted and 469
non-targeted nanoparticles was highly dependent on the EPR effect rather than on the 470
presence of a moiety targeting solely the cancer cells (Fang et al., 2011; Iyer et al., 471
2006; Li and Huang, 2008). 472
Since endothelial cells from tumor blood vessels are more accessible to any nanoparticle 473
injected in the vascular compartment than cancer cells, and being aware of the 474
importance of angiogenesis for the tumor growth and metastasis formation, several 475
therapies targeting angiogenesis have been proposed as a complementary strategy to 476
treat cancer (Abdollahi and Folkman, 2010; Hadj-Slimane et al., 2007).   Therefore, a 477
nanoparticle capable of guiding and concentrating a therapeutic siRNA into endothelial 478
cells from angiogenic tumor blood vessels, in addition to cancer cells, is expected to 479
result in improved tumor accumulation which ultimately will bring additional benefits 480
in the treatment of cancer. 481
The identification of receptors overexpressed on the surface of cancer cells as well as on 482
other cells that constitute the tumor microenvironment, gives rise to an avenue of 483
different forms for therapeutic intervention in oncology. The nucleolin receptor is one 484
of such target as it is overexpressed both on cancer cells and endothelial cells from the 485
angiogenic blood vessels (Christian et al., 2003). Therefore, the F3 peptide, which has 486
been demonstrated to be actively internalized by nucleolin, was chosen as the targeting 487
moiety (Porkka et al., 2002).  488
Overall, the developed F3-targeted sterically stabilized liposomes were characterized by489
high nucleic acid encapsulation efficiency, ability to protect the encapsulated siRNA, a 490
mean size around 200 nm, homogeneous particle size distribution and a surface charge 491
close to neutrality, which are features that make these nanoparticles adequate for a 492
siRNA systemic administration. 493
Moreover, cellular association studies demonstrated that the attachment of the F3 494
peptide to the liposomal surface resulted in a specific and high extent of internalization 495
(more than 10-fold increase relative to the non-targeted counterpart) by both cancer and 496
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endothelial cells from angiogenic blood vessels, but not by non-cancer BJ cells (Figures 497
2 and 3). However, it is important to point out that the improved uptake was not 498
necessarily synonymous of an efficient gene silencing, as reported by Santos et al. 499
(Santos et al., 2010). In this work, the improved cellular association of antagonist G-500
targeted liposomes (similar to the ones used herein) and containing anti-BCL2 siRNA, 501
has not enabled any gene silencing in small cell lung cancer cell lines.  502
In contrast, our eGFP silencing studies demonstrated a significant reduction of eGFP 503
expression in cells treated with anti-eGFP siRNA delivered by F3-targeted liposomes504
(composed of 2 mol% of PEG), both at the protein and mRNA levels, whereas no 505
silencing was observed when cells were treated with the non-targeted counterpart. These 506
results thus indicated that the presence of the F3-peptide brings an important advantage 507
(Figures 3 and 6). 508
With the purpose of obtaining liposomes more stable in respect to size, higher amounts 509
of PEG (4 and 8 mol%) were tested. Despite the improvements achieved at the size 510
level (average reduction of 50 nm), the resulting F3-targeted liposomes were unable to 511
induce eGFP downregulation. Although PEG confers stability during the preparation 512
process and favourable pharmacokinetics characteristics in vivo (Semple et al., 2001),513
Song et al. (Song et al., 2002) demonstrated that the incorporation of 5 mol% of Cer-514
PEG in cationic liposomes complexed with plasmid or antisense oligonucleotides 515
(asODN), slightly impaired cellular internalization but severely inhibited the escape 516
from endosomes of the internalized nucleic acid, thus compromising the transfection 517
efficiency. After endocytosis, lipid mixing between liposomes and the endocytic 518
membrane has to occur, leading to the disruption of the endosomal membrane and the 519
subsequent release of the entrapped nucleic acid. However, the steric barrier imposed by 520
PEG strongly inhibits this process. This effect is more prominent when PEG is attached 521
to lipids with acyl chains longer than 14 C, as the dissociation rate from the liposomal 522
membrane is much slower. Similar results were also reported by others (Remaut et al., 523
2007; Zhang et al., 1999) as well as for  nanocarriers based on polyethylenimine and 524
cyclodextrin (Mishra et al., 2004). Despite this, as the present work aimed at 525
developing liposomes that could mediate systemic delivery of siRNA to breast tumors, 526
CerC16-PEG2000 was deliberately used, since acyl chains longer than 14 C were also 527
associated with longer blood circulation times (Zhang et al., 1999).528
Page 17 of 37
Ac
ce
pte
d M
an
us
cri
pt
17
Our results demonstrated a slight decrease on the rate of internalization of F3-targeted 529
liposomes formed with 8 mol% of PEG (Figure 4). However, the limiting step in respect 530
to gene silencing was rather the inability to escape from the endosomes, as revealed by 531
the observed co-localization between lysosomes and siRNA.  These results have also 532
indicated that the lack of activity of the anti-BCL2 siRNA delivered by antagonist G-533
targeted liposomes previously mentioned (Santos et al., 2010) was probably due to the 534
presence of 10 mol% of CerC16-PEG2000. 535
Taken together, these results demonstrated that with formulations that are internalized 536
through receptor-mediated endocytosis, as it happens with F3-targeted liposomes 537
containing siRNA (Moura et al., 2011), a careful selection of the PEG-derivatized lipid  538
content is required. This demand aims at guaranteeing liposomal size stability without 539
compromising their ability to release the siRNA into the cell cytoplasm, where the RNA 540
interference machinery is located.541
Alternatively, it is interesting to notice that the obstacles imposed by the presence of 542
high amounts of PEG, in this type of formulation, can be overcome through the 543
selection of targeting ligands (such as transferrin) with fusogenic properties (da Cruz et 544
al., 2001). In fact, Mendonça et al. (Mendonca et al., 2010) have developed transferrin-545
targeted liposomes, similar to the liposomes described herein but formed with 8 mol% 546
of PEG, which in vitro resulted in BCR-ABL silencing, at the mRNA and protein levels, 547
in two leukemia cell lines. Moreover, Yang et al. (Yang et al., 2004) have also achieved 548
downregulation of EGFR upon treatment of KB cells with folate-targeted liposomes, 549
composed with 10 mol% of PEG, indicating that folate, like transferrin, can also have 550
some fusogenic properties at acidic pH. Nevertheless, and as discussed, such strategies 551
targeting only cancer cells are not likely to significantly improved in vivo tumor 552
accumulation. 553
Overall, the developed F3-targeted liposomes presented adequate features for 554
intravenous administration of siRNA and led to a significant improvement in the 555
internalization by both cancer and endothelial cells from angiogenic blood vessels, 556
which was further correlated with an effective gene silencing. The present work 557
represents an important contribution towards a nanoparticle with multi-targeting 558
capabilities, both at the cellular and molecular level. 559
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Legends703
Table 1. Physico-chemical characterization of F3-targeted and non-targeted liposomes 704
containing anti-eGFP siRNA. Values are the mean ± SD of at least 3 independent 705
experiments.706
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707
Figure 1. Extent of cellular association of rhodamine-labelled liposomes with human 708
cancer cell lines, endothelial cells and human fibroblasts analyzed by flow cytometry.709
MDA-MB-435S and MDA-MB-231 cancer cells, human microvascular endothelial 710
cells (HMEC-1) or human non-cancer BJ fibroblasts (0.5x106) were incubated with 711
different concentrations of F3-targeted, targeted by a non-specific (NS) peptide and 712
non-targeted liposomes at A) 37ºC or B) 37ºC or 4ºC, during 1 h. After incubation, 713
rhodamine signal was assessed by flow cytometry. Bars are the mean ± SD of 3 714
independent experiments. Two-way ANOVA analysis of variance with Bonferroni´s715
post-test was used for comparison between the referenced samples and F3-targeted 716
liposomes. ***p<0.001; **p<0.01; ns p>0.05.717
718
Figure 2. Cellular association of F3-targeted and non-targeted liposomes with human 719
cancer cell lines, endothelial cells and human fibroblasts, analyzed by confocal 720
microscopy. MDA-MB-435S and MDA-MB-231 cancer cells, human microvascular 721
endothelial cells (HMEC-1) or human non-cancer BJ fibroblasts (2.5x105) were 722
incubated with rhodamine-labelled (red) F3-targeted and non-targeted liposomes,723
encapsulating FITC-labelled siRNA (green), at 0.2 mM of total lipid, during 1 h at 4 or 724
37ºC. The nucleus was stained with DAPI (blue). Cells were fixed with 4% 725
paraformaldehyde, mounted in mowiol and visualized in a point scanning confocal 726
microscope.727
728
Figure 3. Effect of the number of transfections, poly(ethylene glycol) content or 729
treatment duration on eGFP levels. (A) MDA-MB-435S-eGFP and (B) MDA-MB-231-730
eGFP cell lines were transfected twice with different concentrations of anti-eGFP731
siRNA encapsulated in F3-targeted or non-targeted liposomes, incorporating 2 mol% of 732
CerC16-PEG2000. A non-specific siRNA encapsulated in F3-targeted liposomes was 733
included as control (CTR). Alternatively, only a single treatment was performed. EGFP 734
levels were evaluated by flow cytometry 96 h after the beginning of the experiment. (C) 735
EGFP levels were evaluated 48 h after one single treatment with liposomes composed 736
of 2 mol% of CerC16-PEG2000. (D) MDA-MB-435-eGFP cells were transfected twice as 737
in A) but with liposomes formed with 4 mol% of CerC16-PEG2000. Bars are the mean ± 738
SEM of 3 independent experiments. Two-way ANOVA analysis of variance with 739
Bonferroni´s post-test was used for multiple comparisons. Asterik symbols represented 740
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the significance level of the difference between the referenced formulations and F3-741
targeted liposomes containing the anti-eGFP siRNA (***p<0.001; **p<0.01; *p<0.05); 742
cardinal symbols represented the significance level of the difference between eGFP 743
levels at the referenced time point (###p<0.001) when comparison was established 744
between eGFP silencing at 48 h and 96 h.  745
746
Figure 4. Effect of PEG content on the extent of cellular association of F3-targeted 747
liposomes by MDA-MB-435S cancer and HMEC-1 endothelial cells. Half-million cells 748
were incubated with rhodamine-labelled F3-targeted liposomes incorporating 2 or 8 749
mol% of CerC16-PEG2000, at 0.2 mM of total lipid, for 1 h at 37ºC. After incubation, 750
rhodamine signal was assessed by flow cytometry. Bars are the mean ± SD of 3 751
independent experiments. One-way ANOVA analysis of variance with Bonferroni´s 752
post-test was used for comparison between F3-targeted liposomes incorporating 2 and 8 753
mol% of PEG (ns p>0.05).754
755
Figure 5. Intracellular trafficking of siRNA encapsulated in F3-targeted liposomes. 756
Cells were incubated with liposomes prepared either with A) 8 or B) 2 mol% of PEG,757
containing a FITC-labelled siRNA (green), during 4 h at 37ºC. Afterwards, lysosomes 758
were labeled with LysoTracker Red (red) and live cells visualized in a point scanning 759
confocal microscope.760
761
Figure 6. Effect of anti-eGFP siRNA encapsulated in different liposomal formulations 762
on the eGFP mRNA in MDA-MB-435S-eGFP cells. Cells were transfected at 0 and 48 763
h, with either anti-eGFP siRNA encapsulated in F3-targeted or non-targeted liposomes, 764
containing 2 mol% of CerC16-PEG2000, or with the control siRNA encapsulated in the 765
former. EGFP mRNA levels were assessed 24 h after the second transfection by qRT-766
PCR and in comparison with the mRNA levels of untreated cells.  Bars are the mean ± 767
SD of 3 independent experiments. Two-way ANOVA analysis of variance with 768
Bonferroni´s post-test was used for comparison between the referenced samples and F3-769
targeted liposomes containing the anti-eGFP siRNA (**p<0.01, *p<0.05).770
771
772
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Table 1772
F3-targeted liposomes Non-targeted liposomes
PEG 
(mol%)
Size
(nm)
Polidispersity 
index
Encaps.
efficiency
(%)
Size
(nm)
Polidispersity 
index
Encaps.
efficiency
(%)
2 254.4 
±  26.55
0.144 
±  0.03
95.72 
±  8.44
130.3 
± 13.32
0.076
±  0.05
99.77 
±  8.48
4 194.7 
± 16.40
0.149 
± 0.03
95.99
± 21.15
109.0 
±  10.82
0.145 
±  0.05
90.32
± 12.42
8 210.2 
± 21.74
0.146 
±  0.06
76.86
± 16,63
112.1 
±  4.51
0.281 
±  0.05
87.53
± 18.32
773
774
775
776
777
778
779
780
781
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